Ocrelizumab treatment in multiple sclerosis: A Danish population-based cohort study

Publikation: Bidrag til tidsskrift/Konferencebidrag i tidsskrift /Bidrag til avisTidsskriftartikelForskningpeer review

DOI

  • Luigi Pontieri, Københavns Universitet
  • ,
  • Morten Blinkenberg, Københavns Universitet
  • ,
  • Stephan Bramow, Københavns Universitet
  • ,
  • Viktoria Papp
  • Peter V. Rasmussen
  • Matthias Kant, Syddansk Universitet
  • ,
  • Jakob Schäfer, Aalborg Universitet
  • ,
  • Henrik K. Mathiesen, Københavns Universitet
  • ,
  • Michael B. Jensen, Københavns Universitet
  • ,
  • Georgi Sirakov, Aarhus Universitet
  • ,
  • Jonas M. Berg
  • ,
  • Tine I. Kopp, Københavns Universitet
  • ,
  • Hanna Joensen, Københavns Universitet
  • ,
  • Finn Sellebjerg, Københavns Universitet
  • ,
  • Melinda Magyari, Københavns Universitet

Background and purpose: Real-world evidence regarding the effectiveness and safety of ocrelizumab for the treatment of multiple sclerosis (MS) is limited. The aim was to evaluate the effectiveness and safety of ocrelizumab treatment for MS in a real-world setting. Methods: A nationwide population-based cohort study was conducted where clinical and magnetic resonance imaging data of MS patients enrolled prospectively in the Danish Multiple Sclerosis Registry who initiated ocrelizumab treatment between January 2018 and November 2020 were analyzed. Results: A total of 1104 patients (85.7% relapsing–remitting MS [RRMS], 8.8% secondary progressive MS [SPMS], 5.5% primary progressive MS [PPMS]) were included, with a median follow-up period of 1.3 years. At baseline, the mean age was 41.4 years in the RRMS group, 44.5 years in the PPMS group and 50.3 years in the SPMS group. Median Expanded Disability Status Scale score was 2.5, 3.5 and 5.5, respectively. Most RRMS and SPMS patients had received previous disease-modifying therapies (87.5% and 91.8%, respectively), whereas PPMS patients were mostly treatment naïve (78.7%). After ocrelizumab initiation, 9.3% of the patients experienced a relapse and 8.7% a 24 weeks confirmed disability worsening. Conversely, 16.7% showed a 24 weeks confirmed disability improvement. After ~1 year of treatment, most patients (94.5%) were free of magnetic resonance imaging activity. Ocrelizumab was generally well tolerated, as side effects were only reported for 10% of patients, mostly consisting of infusion-related reactions and infections. Conclusions: It is shown that most MS patients treated with ocrelizumab are clinically stabilized and with an adverse event profile consistent with the experience from the pivotal clinical trials.

OriginalsprogEngelsk
TidsskriftEuropean Journal of Neurology
Vol/bind29
Nummer2
Sider (fra-til)496-504
Antal sider9
ISSN1351-5101
DOI
StatusUdgivet - feb. 2022

Se relationer på Aarhus Universitet Citationsformater

ID: 272049992